Platelet survival studies in man with diisopropylphosphorofluoridate (DF32P). Some observations in patients with hypocoagulability, 'hypercoagulability' and platelet disorders.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D000925:Anticoagulants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000503:physiopathology; D001778:Blood Coagulation Disorders / Q000503:physiopathology*; D001791:Blood Platelet Disorders / Q000503:physiopathology; D001792:Blood Platelets / Q000502:physiology*; D002648:Child; D005167:Factor VII; D005260:Female; D006457:Hemoglobinuria, Paroxysmal; D006467:Hemophilia A / Q000503:physiopathology; D006801:Humans; D066298:In Vitro Techniques; D007531:Isoflurophate / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010759:Phosphorus Isotopes; D013921:Thrombocytopenia / Q000503:physiopathology
D000925:Anticoagulants; D010759:Phosphorus Isotopes; D007531:Isoflurophate; D005167:Factor VII